KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to -$1.15.

  • Xenon Pharmaceuticals' EPS (Weighted Average and Diluted) fell 4197.53% to -$1.15 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.89, marking a year-over-year decrease of 3794.33%. This contributed to the annual value of -$3.01 for FY2024, which is 1019.39% down from last year.
  • Xenon Pharmaceuticals' EPS (Weighted Average and Diluted) amounted to -$1.15 in Q3 2025, which was down 4197.53% from -$1.07 recorded in Q2 2025.
  • Xenon Pharmaceuticals' EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.35 during Q1 2022, with a 5-year trough of -$1.15 in Q3 2025.
  • Its 5-year average for EPS (Weighted Average and Diluted) is -$0.69, with a median of -$0.64 in 2023.
  • In the last 5 years, Xenon Pharmaceuticals' EPS (Weighted Average and Diluted) plummeted by 8000.0% in 2023 and then surged by 158.73% in 2024.
  • Over the past 5 years, Xenon Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.48 in 2021, then dropped by 18.75% to -$0.57 in 2022, then dropped by 12.28% to -$0.64 in 2023, then tumbled by 59.55% to -$1.02 in 2024, then dropped by 12.62% to -$1.15 in 2025.
  • Its EPS (Weighted Average and Diluted) was -$1.15 in Q3 2025, compared to -$1.07 in Q2 2025 and -$0.83 in Q1 2025.